🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Incredible learning opportunity UMN Critical Care Cardiology Education Summit’s 3rd Annual CV Crit Care Summit. Exciting to witness the evolution of a rapidly growing field (with great people). Bonus: got to tour their ECMObile. Innovation in action. #CCCES25

Another Exercizumab study! 💪 Among 22,716 childhood cancer survivors: ⚠️ Obesity = ↑ risk of future cancers (solid, CNS, skin) 🏃‍♂️ Physical activity = protective effect across cancer types Lifestyle does matter, even decades later. #Survivorship #ChildhoodCancer #Prevention

Congrats Lev Bubis on this NET research grant! 🎉👏🏻 Great work to define priorities in NET surgical care research with CUTNETs Group Thanks CNETS for supporting early career investigators in NETs research 🙏🏻🦓

I’m glad I’m not saying just positive things on here 😂 There’s room to do so much better for our patients. They deserve the best!

Overall Survival and Quality-of-Life Superiority in Modern Phase 3 Oncology Trials: A Meta-Epidemiological Analysis | Oncology | JAMA Oncology | JAMA Network jamanetwork.com/journals/jamao…

Life Update: I am finally an oncologist! So glad to graduate from fellowship UI Holden Comprehensive Cancer Center along with Greg Kirkpatrick Justin Buzick Samragnyi Madala Ben Staum Luna Acharya, MD MA Three years just flew by! Now time to live the dream of giving my best to treat gastrointestinal and neuroendocrine

🔬 Colorectal Cancer (CRC) Screening: Evolving Landscape 🧻🩸🧪 📊 CRC = 2nd leading cause of cancer death, 3rd most common globally 👁️‍🗨️ Begins as adenomatous/serrated polyps → Advanced precursor lesions (APLs) → invasive cancer 🎯 Goal of screening: Detect early-stage CRC &

🚨 AI Revolution in Stage II CRC! 🚨 📌 IRIS-CRC, a new AI-driven tool, outperforms traditional guideline-based stratification in predicting prognosis for stage II colorectal cancer (CRC) 🧠🖥️ 🔍 Combines: •Deep learning CT analysis (STAR-CRC 🌀) •Key pathological features

🚨 New Hope in HER2+ GEA! 💉 Zanidatamab + chemo as 1L tx shows powerful efficacy in advanced HER2+ gastro-oesophageal adenocarcinoma (NCT03929666): ✅ ORR: 76.2% ✅ Median PFS: 12.5 mo ✅ Median OS: 36.5 mo ✅ DCR: 88% ✅ Durable responses: median DoR 18.7 mo ⚠️ Main

👏 Huge congratulations to Nicole Grogan Fleege, MD on receiving the Faculty of the Year award! So richly deserved! Your unique ability to make an extremely complex disease like breast cancer easy to understand is nothing short of remarkable. You’ve set the bar so high on how I should take

Udhayvir Grewal Thanks so much, Udhay! This award truly means the world to me. It’s an honor to work with such a great group of fellows. And seeing the first class of fellows I ever worked with graduate last night was really special! I’m proud of you all!

As always, my thanks to ASCO for letting patient advocates attend the annual meeting in person or online for free. It helps us spread information -- and hope -- to other patients.

Excited to share that our project LUCID (Leveraging Unstructured Clinical Information for Discovery) was selected for the Northwell Health Cancer Institute Pilot Award for Mentoring in Cancer Research! I’m looking forward to deepening my collaboration with my mentee, Ashish

Don’t forget: many landmark trials at #ASCO25 (e.g. ATOMIC, PDIGREE, CHALLENGE) were powered by National Cancer Institute / NCTN Such studies ask high-impact, public-benefit questions that industry often won’t/can't answer. Alliance for Clinical Trials in Oncology CCTG ECOG-ACRIN Cancer Research Group NRG Oncology SWOG Cancer Research Network

As I reflect on ASCO 25 I left with gratitude for:incredible opportunities; mentors who celebrate your work and push you; friends who are there for you; practice changing data. Hope to see you in Chicago next year. Tim Brown, MD MSCE Oncology Brothers Udhayvir Grewal

Dr. Nina Niu Sanford I already tell my patients with cancer (or those in remission) to exercise. My conversation will now include the results of this trial as further encouragement.

You can find flaws in any study, but CHALLENGE has no major issues. Musculoskeletal side effects are expected with exercise; we can’t wrap patients in cotton post-treatment—they must return to life. If quality of life improves, minor side effects shouldn’t be overstated.